Ethics Approval Granted for BMB18 Human Clinical Trial
Filed with ASX · · 5 pages · English
Watch Biome Australia's latest callBiome Australia (ASX:BIO) Q1 2026 Earnings Call · Replay · Oct 22, 2025Read the transcript of Biome Australia (ASX:BIO) Q1 2026 Earnings Call● Randomised, double-blind, placebo-controlled trial recruiting 240 participants to investigate the efficacy of proprietary strain Lactobacillus plantarum BMB18 (DSM 35214) in adults experiencing digestive symptoms, sleep and mood disturbances ● La Trobe University Human Research Ethics Committee grants ethics approval, clearing the final regulatory prerequisite for the trial to commence in Februa
Story so far
Earlier from Biome Australia
- Biome secures distribution with Fullscript Canada
- Quarterly Activities & Cashflow Report
- Trading Update
- Biome Launches Human Clinical Trial on BMB18
- Q1 FY26 Revenue Guidance
Later from Biome Australia
- Appendix 4D & Half Yearly Report
- Biome First Half FY26 Results and Highlights
- Patent Application Filed for Probiotic Strain BMB18
- Probiotical Exclusive Supply Agreement Extended
- BMB18 clinical trial expands to dual site
Follow Biome Australia into a list and get an email when it puts out news.
Follow Biome Australia